This study could significantly impact BioNTech’s stock performance and investor sentiment, especially if the results demonstrate a breakthrough in breast cancer treatment. The involvement of ...

Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

In August 2025, BioNTech SE organized a Phase II study in participants with untreated extended-stage small-cell lung cancer (ES-SCLC) (Cohort 1) or small-cell lung cancer (SCLC) which has progressed ...